Autoimmune disorders can be treated by Type 2 diabetes medicine: Study | Health - Hindustan Times
close_game
close_game

Autoimmune disorders can be treated by Type 2 diabetes medicine: Study

ANI | | Posted by Tapatrisha Das, Washington
May 26, 2023 11:22 AM IST

The study states that researchers discovered a medicine used for treating Type 2 Diabetes, that can treat autoimmune diseases as well.

Researchers at Swansea University discovered that a medicine frequently used to treat type 2 diabetes might possibly be used to treat autoimmune illnesses.

Autoimmune disorders can be treated by Type 2 diabetes medicine: Study(Freepik)
Autoimmune disorders can be treated by Type 2 diabetes medicine: Study(Freepik)

Academics at the University's Faculty of Medicine, Health and Life Science have found that the drug, canagliflozin (also known as Invokana), could be used to treat autoimmune disorders such as rheumatoid arthritis and systemic lupus erythematosus as it targets T-cells, which form an essential component of the immune system. Canagliflozin is a drug that controls blood sugar levels in people with type 2 diabetes, however researchers have found an unexpected role for the drug involving the human immune system.

Get ready to catch the final stages of the World Cup only on Crickit. Anytime, Anywhere. Explore now!

Existing research has reported that targeting T-cell metabolism in autoimmunity can lead to therapeutic benefits. T-cells are a type of white blood cell that help the body fight infections and diseases, but in autoimmune diseases they have been observed to attack healthy tissues.

ALSO READ: The cause of autoimmunity in patients with type 1 Diabetes: Research

The new study, funded by the Medical Research Council and published today in the journal Cell Metabolism, found that canagliflozin dampens down T-cell activation, suggesting that the drug could be repurposed as a treatment for T-cell driven autoimmunity.

Dr Nick Jones, senior author who led the study said: "Our findings are significant as they provide the foundation for the clinical development of canagliflozin for the treatment of certain autoimmune diseases. As the drug is already widely used and has a known safety profile in humans, it could potentially reach clinic quicker than any new drugs developed and bring valuable benefits more swiftly to patients with autoimmune disorders."

Ben Jenkins, first author and postdoctoral researcher at Swansea said: "Identifying new roles for drugs that are currently being used in other disease settings is an exciting area of research. Given that our research primarily targets the metabolism of immune cells, we hope that the potential therapeutic benefits of our findings are applicable to a wide range of conditions."

The researchers are hopeful that canagliflozin will enter a clinical trial to treat certain autoimmune disorders in the future. (ANI)

Get World Cup ready with Crick-it! From live scores to match stats, catch all the action here. Explore now!.

Catch your daily dose of Fashion, Taylor Swift, Health, Festivals, Travel, Relationship, Recipe and all the other Latest Lifestyle News on Hindustan Times Website and APPs.
This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.
SHARE THIS ARTICLE ON
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Tuesday, June 25, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On